Enrolment of subjects is commencing in these additional sites. Two of these sites also participated in the European Feasibility Study, results of which were presented in mid-2013.
Mr. Peter Crosby, Mainstay’s Chief Executive Officer, noted "We are pleased to expand the clinical trial to the UK sites as planned. This continues our steady progress towards regulatory approval and commercialization of ReActiv8. When available, ReActiv8 has the potential to change the lives of the millions of people who suffer from Chronic Low Back Pain."
The clinical trial of ReActiv8 started in March 2014, and several sites in Australia and Belgium continue to actively enrol subjects. The purpose of the clinical trial is to investigate ReActiv8 as a treatment for adults with debilitating Chronic Low Back Pain who have few other treatment options.
